NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

PDS Biotech’s PDS01ADC Delivers Impressive 78% Response Rate in Advanced Colorectal Cancer Trial

PDS Biotech drug PDS01ADC improved tumor shrinkage and survival in colorectal cancer trials, showing strong early results.

PDS Biotech’s PDS01ADC Delivers Impressive 78% Response Rate in Advanced Colorectal Cancer Trial
Credit: PDS Biotech
Already have an account? Sign in.
04/15/2026 · 11:16 AM
PDSB
/ Don’t stop at just one post.

Related↓

PDS Biotech Submits Protocol Amendment for Faster Cancer Drug Approval
01/09/2026 · 11:37 AM

PDS Biotech Submits Protocol Amendment for Faster Cancer Drug Approval

PDS Biotechnology updates Phase 3 trial protocol with FDA to potentially speed up approval of PDS0101 for HPV-related head and neck cancer treatment.

/ Subscriber only
/ Read more

Feed↓

Analysts Reiterate Buy Ratings on Intellia as lonvo-z Shows Deeper Benefits in HAELO Trial
06/15/2026 · 11:12 AM

Analysts Reiterate Buy Ratings on Intellia as lonvo-z Shows Deeper Benefits in HAELO Trial

Intellia’s one-time gene therapy cut HAE attacks ~90%, boosting hopes for a lasting treatment; FDA review underway, launch possible in 2027.

/ Subscriber only
Oppenheimer Sees 440% Upside in Acrivon Therapeutics as Key ACR-368 Data Approaches
06/15/2026 · 10:15 AM

Oppenheimer Sees 440% Upside in Acrivon Therapeutics as Key ACR-368 Data Approaches

Cancer drug ACR-368 shows strong early results in endometrial trials biomarker-driven response.

/ Subscriber only
Salesforce Acquires Fin for $3.6 Billion to Strengthen AI Customer Agents
06/15/2026 · 9:49 AM

Salesforce Acquires Fin for $3.6 Billion to Strengthen AI Customer Agents

The deal will expand its Agentforce platform with advanced AI-powered customer service agents.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2026
Email address Subscribe